Skip to main content


RheumNow Podcast square

Methotrexate Monitoring (5.13.2022)

May 13, 2022

Dr. Jack Cush reviews the news and journal reports from the past week on Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.

  1. Risk factors for readmission among 132,400 #SLE hospitalizatiions included

Read Article

Wiki Guidelines Approach to Pyogenic Osteomyelitis

May 12, 2022

A crowd sourced, WikiGuidelines approach to clinical treatment guideline development for pyogenic osteomyelitis yielded 7 important clinical questions, 2 clear treatment recommendations and 5 topic reviews to inform future treatment or investigations.

Some clinical scenarios may be

Read Article
RheumNow Podcast square

$30 Billion and Counting (4.29.2022)

Apr 29, 2022

Dr. Jack Cush reviews the news and journal reports and takes viewer questions this week.

Read Article
RheumNow Podcast square

Pre-exposure Prophylaxis for COVID-19 (4.22.22)

Apr 22, 2022

Dr. Jack Cush discusses the news and recent journal reports from last weeks, and answers viewer questions from #ACA - Ask Cush Anything.

Read Article

COVID-19 Vaccination Uptake and Perceptions in Rheumatic Patients

Apr 21, 2022

Putman et al has reported vaccine survey results from the COVID-19 Global Rheumatology Alliance (C19-GRA) in Lancet Rheumatology showing the uptake and vaccine hesitancy among people with rheumatic diseases (RMD).

Survey data from 7005 vaccinated and unvaccinated, adult RMD respondents from 102

Read Article

Evusheld as Protective Therapy in High Risk COVID-19 Patients

Apr 21, 2022

A single dose of the monoclonal-antibody AZD7442 (combination of tixagevimab and cilgavimab) has been shown to be safe and effective as prophylaxis against COVID-19 infection in high risk individuals who tested positive for COVID-19. 

Both MAbs are neutralizing antibodies against SARS

Read Article
RheumNow Podcast square

Male vs. Female Responders (4.15.2022)

Apr 15, 2022

Dr. Jack Cush reviews the news and journal Reports from the past week on - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic. 

  1. Downward Effects! Real world data from 22,934 UK #RA pts

Read Article
virtual online learning home office zoom

Consensus Best Practices for Virtual Care in Rheumatology

Apr 13, 2022

The Canadian Rheumatology Association’s (CRA) Telehealth Working Group (TWG) has developed a series of best practice statements for the virtual care in adult and pediatric rheumatology patients.

Read Article

ACR Fellow Training Subcommittee Report on Pandemic Experiences

Apr 11, 2022

Arthritis & Rheumatology has publish an ACR Subcommittee report on how the COVID-19 pandemic affected fellows and their training. 

Read Article
RheumNow Podcast square

RheumNow Podcast – What You Do For & What You Do To the Patient (4.8.2022)

Apr 08, 2022

Dr. Jack Cush reviews the news and journal articles from the past week and discusses the use of fibroscan in RA, steroid hip injections in OA and famous quotes from a famous cardiologist.

  1. CorEvitas Registry study of173 Axial #PsA pts showed 6 mos of bDMARD/tsDMARD resulted

Read Article
Infection in lupus is suggested by very high CRP, PMN-lymph ratio (NLR) Plt-lymph ratio(PLR). Study of 104 hospitalized SLE found all very high w/ infx & Combined cutoffs of CRP >20 mg/L, NLR >3.5, PLR >151 had 87 sensitivity & 81% specificity for infx
Dr. John Cush @RheumNow( View Tweet )
Mar 28, 2022

Are Shoulder Conditions Incited by Vaccination?

Mar 21, 2022

A retrospective cohort study from Kaiser Permanente Southern California intramuscular vaccination given between 2016 and 2017 shows a small but significant increase in shoulder conditions, reported as an adverse event (AE) following intramuscular vaccination in the deltoid muscle. 

Read Article
RheumNow Podcast square

Consequences of TNF inhibition (3.18.2022)

Mar 18, 2022

This week we're going to talk about the downside of TNF inhibitors, a few interesting observations in gout, and yes, kids do get COVID. We're also going to preview what's coming in April (hint: it's about PsA). This and more as Dr. Jack Cush reviews the news and journal articles from the past

Read Article

Disappointment Behind Acute Gout Hospitalizations

Mar 16, 2022

Analysis of emergency department visits from two UK hospitals shows a high rate of hospitalization, and low use of urate-lowering therapies (ULT) and treat-to-target (T2T) management. 

Between 2017 and 2020 there were 1,220 emergency attendances for gout flares -  23.5% required

Read Article
Korean study (TB endemic area) shows the risk of mTB & nontuberculous mycobact infx (NTM) are equal and nearly doubled in RA pts on TNFi. Among 4356 RA (1089 on TNFi) NTM & TB rates were 328- and 341/100K PY (US rate is 6/100K PY)
Dr. John Cush @RheumNow( View Tweet )
Mar 14, 2022

Baricitinib’s COVID-19 Efficacy in the RECOVERY Trial

Mar 08, 2022

Pre-print results of the RECOVERY Trial has shown that when baricitinib (BAR) is given to hospitalized severe COVID-19 patients, it results in significantly less mortality. BAR joins dexamethasone and tocilizumab as anti-inflammatory treatments capable of reducing the risk of death in COVID-

Read Article

Tocilizumab Works Best in Non-Mechanical Ventilated COVID-19 Patients

Mar 04, 2022

JAMA has published a meta-analysis of 15 studies of hospitalized patients with COVID-19 treated with tocilizumab and corticosteroids, showing that a clinically meaningful mortality benefit from tocilizumab (and steroids) was best seen in those not requiring invasive mechanical ventilation (

Read Article
With H. Zoster on JAK inhib; you can continue JAKi @ low risk. Study of 416 RA pts on JAKi, 8% HZ reactivation (age 60 yrs, 42% Pred) after 11 mos. 72% cont JAKi during HZ, 15% temporarily D/C & resumed. Only 1 pt had HZ re-reactivation

Dr. John Cush @RheumNow( View Tweet )

Mar 03, 2022

MMWR - NFL Study on When to Be Released if COVID(+)

Feb 25, 2022

MMWR has reported the results of the National Football Leagues (NFL) change in SARS-CoV-2 testing program that went into effect in December 2021, at the height of the Omicron variant surge, showing that among those with asymptomatic infection, only half were PCR test negative and could return

Read Article

Low COVID-19 Vaccine Risks in Rheumatic Patients

Feb 23, 2022

Data from the European Alliance of Associations for Rheumatology Coronavirus Vaccine registry shows that patients with with inflammatory or noninflammatory rheumatic and musculoskeletal disease have similar adverse event rates as the general public.

Data from this registry was

Read Article
RheumNow Podcast square

Hand OA and Heroes in Rheumatology (2.11.2022)

Feb 11, 2022

Interesting reports this week about dementia, who gets hand OA and a great list of women Heroes and Pillars of Rheumatology. Tune in as Dr. Jack Cush reviews the news and journal articles from this past week in

Read Article
RheumNow Podcast square

An Ounce of Prevention (2.4.2022)

Feb 03, 2022

Dr. Jack Cush reviews the news and journal reports from this past week on  He discusses the GI side effects of IL-17 inhibitors, downstream revenues from rheumatology care and dietary prevention of gout. 

Read Article
ACR, guidance, guidelines

ACR Newly Revised COVID-19 Vaccine Clinical Guidance for RMD Patients

Jan 31, 2022

The ACR has updated its clinical guidance for the use of COVID-19 vaccination in patients with musculoskeletal disorders (MSK). 

Read Article
RheumNow Podcast square

The Last Word on JAK Inhibitor Safety & 1133 Study (1.28.2022)

Jan 28, 2022

Dr. Jack Cush reviews the news and journal articles from the past week on  This week a trifecta of Gout reports and the last word on the ORAL Surveillance study...

Read Article
virus,COVID,Vaccine, booster

MMWR: Booster Vaccine Efficacy in Immunosuppressed Patients

Jan 27, 2022

For adults aged ≥18 years who received 2 doses of an mRNA COVID-19 vaccine, a third dose increased vaccine effectiveness (prevention of hospitalization) among adults without (82% to 97%) and with immunocompromising conditions (69% to 88%), with near similar efficacy.


Read Article